Key facts
- Notable investors include Chapter One, Ben Reis.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Gnomica
- ·The full record, as it builds
Funding rounds
No funding rounds for Gnomica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gnomica
Developer of small-molecule drug inhibitors designed to address treatment resistance in cancer by targeting bacterial functions within the human body. The company offers drug discovery and development focused on bacterial pathways linked to cancer progression and resistance, enabling oncology researchers and healthcare developers to explore new therapeutic approaches that account for microbial influence on treatment response and disease outcomes.
- Sector
- Healthcare
- HQ
- Center District, Israel
- Founded
- 2025
- Employees
- 5
- Website
- gnomica.com/
- Ownership
- Privately Held (backing)
Gnomica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gnomica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gnomica in its N-PORT filings yet. We sweep new filings monthly.